Kolltan Pharmaceuticals said it has signed an agreement to license a monoclonal antibody from MedImmune.
The New Haven company hopes to initiate Phase 1 clinical testing of the antibody, which targets the HER3 cell surface receptor, in early 2014. Maryland-based MedImmune is the biologics R&D arm of AstraZeneca.
“Kolltan is excited to advance this innovative product candidate into clinical testing for the broad potential treatment of cancer patients where this target plays a role,” Dr. Jerry McMahon, president and CEO of Kolltan, said in a statement.
The financial terms of the deal were not disclosed, but allows for future sharing of costs, risks and profits for the antibody, Kolltan said.
